The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
February 16th 2025, 5:00pm
Transplantation and Cellular Therapy Meetings
CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.
February 15th 2025, 9:45pm
Transplantation and Cellular Therapy Meetings
Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.
February 15th 2025, 8:15pm
Genitourinary Cancers Symposium (ASCO GU)
No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.
February 15th 2025, 7:58pm
Genitourinary Cancers Symposium (ASCO GU)
Nivolumab in combination with cabozantinib displayed a long-term PFS benefit in patients with treatment-naive advanced RCC.
February 15th 2025, 7:57pm
Genitourinary Cancers Symposium (ASCO GU)
CBM588 plus cabozantinib and nivolumab shows early efficacy in metastatic renal cell carcinoma.
February 15th 2025, 7:53pm
Genitourinary Cancers Symposium (ASCO GU)
Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.
February 15th 2025, 7:33pm
Genitourinary Cancers Symposium (ASCO GU)
The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.
February 15th 2025, 7:26pm
Genitourinary Cancers Symposium (ASCO GU)
Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.
February 15th 2025, 7:10pm
Genitourinary Cancers Symposium (ASCO GU)
Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.
February 15th 2025, 7:04pm
Genitourinary Cancers Symposium (ASCO GU)
Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.
February 15th 2025, 6:36pm
Genitourinary Cancers Symposium (ASCO GU)
An ER model analysis showed that 1.34 mg of tivozanib provided a greater decrease in tumor size and may be more tolerable than an 0.89-mg dose in RCC.
February 15th 2025, 6:19pm
Transplantation and Cellular Therapy Meetings
Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.
February 15th 2025, 4:51pm
Genitourinary Cancers Symposium (ASCO GU)
Data spotlighted that the addition of perioperative durvalumab to radical cystectomy and adjuvant chemotherapy improved outcomes in MIBC.
February 15th 2025, 4:35pm
Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.
February 15th 2025, 4:21pm
Genitourinary Cancers Symposium (ASCO GU)
Enfortumab vedotin plus pembrolizumab maintains compelling benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.
February 14th 2025, 11:06pm
Transplantation and Cellular Therapy Meetings
One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.
February 14th 2025, 10:54pm
Genitourinary Cancers Symposium (ASCO GU)
Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.
February 14th 2025, 10:38pm
Transplantation and Cellular Therapy Meetings
MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.
February 14th 2025, 10:34pm
Transplantation and Cellular Therapy Meetings
Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.